(Total Views: 601)
Posted On: 05/19/2024 7:26:13 PM
Post# of 153965
This makes sense in a perfect world but I guess we just have to wait and see.
“Using both Keytruda and leronlimab together would not be a drug conjugate so it wouldn't be considered a new drug by the FDA or a patentable new drug. So Keytruda would still be standing on it's soon to expire original patent. It is possible they could conjugate the drugs considering they're both monoclonal antibodies. But that would add nothing of value to leronlimab's effectiveness. Much better to buy out Cytodyn, get leronlimab approved and leave Keytruda in the dustbin”
Investors Hangout: https://investorshangout.com/post/view?id=669...z8aigElsn0
“Using both Keytruda and leronlimab together would not be a drug conjugate so it wouldn't be considered a new drug by the FDA or a patentable new drug. So Keytruda would still be standing on it's soon to expire original patent. It is possible they could conjugate the drugs considering they're both monoclonal antibodies. But that would add nothing of value to leronlimab's effectiveness. Much better to buy out Cytodyn, get leronlimab approved and leave Keytruda in the dustbin”
Investors Hangout: https://investorshangout.com/post/view?id=669...z8aigElsn0
(3)
(0)
